Milla Pharmaceuticals Inc.

What Milla Pharmaceuticals Inc. does

Milla Pharmaceuticals Inc. is a US specialty pharmaceutical company focused on developing and commercializing FDA-approved generic injectable medications. It is wholly owned by the Belgian pharmaceutical group A.forall, headquartered in White Bear Lake, Minnesota, and operates as the US commercialization arm of a group that collectively sells roughly 30 molecules across the United States and Europe. The company's marketed portfolio spans multiple therapeutic categories and includes Dihydroergotamine Mesylate Injection (migraine), Phenylephrine Injection (hypotension), Piperacillin and Tazobactam for Injection (antibiotic), Sodium Acetate Injection (electrolyte), Tranexamic Acid Injection (antifibrinolytic, also offered under a Novaplus sub-brand), and Tromethamine Injection (metabolic acidosis). Several of these products are positioned to address active FDA drug shortages and have been granted Competitive Generic Therapy (CGT) exclusivity, including 180-day CGT exclusivity for Sodium Acetate Injection 2 mEq/mL.

The business model is commercialization of FDA-approved generic injectables through a multi-channel US distribution network spanning wholesalers, distributors, hospitals, infusion care clinics, pharmacies, and retirement homes. Until recently Milla sold primarily through channel partners including Sandoz (which launched Milla-developed injectable acetaminophen in 2020) and Woodward Pharma Services, but the company began directly commercializing products under its own label in January 2025 with the Tromethamine Injection launch, followed by direct commercialization of Sodium Acetate Injection 2 mEq/mL in July 2025. Milla has stated openness to additional partnership arrangements, including institutional product commercialization, authorized generics, NDA/ANDA acquisition, licensing, and co-development, indicating a hybrid go-to-market that pairs organic ANDA approvals with partner-driven and potentially inorganic growth.

The broader A.forall group employs approximately 144 staff globally and runs a fully stocked pipeline of niche, complex, and added-value generics. Milla itself is a privately held corporation, with no public listing or disclosed external institutional investment, and revenue figures are not publicly disclosed.

Name

Milla Pharmaceuticals Inc.

Legal name

Milla Pharmaceuticals Inc.

Website

https://millapharmaceuticals.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

Milla Pharmaceuticals Inc. is the US subsidiary of Belgium's A.forall group, developing and commercializing FDA-approved generic injectable medications across multiple therapeutic categories for US hospitals, infusion clinics, wholesalers, distributors, pharmacies, and retirement homes.

Ownership category

akta.pro rank

Product category

Generic Injectable Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industry

Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)

Keywords

• Generic injectable pharmaceuticals
• FDA-approved generic drugs
• Hospital injectable medications
• Niche complex generics
• Pharmaceutical ANDA approvals

Headquarters

HQ city

Minnetonka

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Generic Injectable Pharmaceuticals Sales: Revenue generated through the sale of FDA-approved generic injectable medications to healthcare providers, hospitals, and clinics. Products include Dihydroergotamine Mesylate, Phenylephrine, Piperacillin and Tazobactam, Sodium Acetate, Tranexamic Acid, and Tromethamine injections.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels2 records

Core offering

Milla Pharmaceuticals Inc. develops and commercializes FDA-approved generic injectable pharmaceutical products for the U.S. market, targeting niche, complex, and added-value molecules. The company distributes its injectable medications through wholesalers, distributors, hospitals, infusion care clinics, pharmacies, and retirement homes, with a portfolio spanning cardiovascular, antibiotic, electrolyte, antifibrinolytic, antimigraine, and metabolic acidosis therapeutic categories. Products are sold both directly under the Milla label and through partnerships with established distributors such as Sandoz and Woodward Pharma Services.

Product overview

Milla Pharmaceuticals Inc. is a specialty pharmaceutical company focused on commercializing FDA-approved generic injectable medications for the U.S. market. The company's portfolio includes injectable drugs across multiple therapeutic categories: cardiovascular agents (Phenylephrine), antibiotics (Piperacillin and Tazobactam), electrolyte supplements (Sodium Acetate), antifibrinolytics (Tranexamic Acid), antimigraine treatments (Dihydroergotamine Mesylate), and metabolic acidosis treatments (Tromethamine). These products are distributed through an extensive network of wholesalers, distributors, hospitals, and infusion care clinics. Milla operates as the U.S. subsidiary of the Belgian A.forall pharmaceutical group.

Differentiator

Problem solved

Functional benefit

Brands

• Novaplus: A sub-brand product line for Tranexamic Acid Injection 100mg/mL marketed under Novaplus designation

Products and services

• Dihydroergotamine Mesylate Injection 1mg/mL Generic injectable dihydroergotamine mesylate (1mg/mL in 1mL ampules) used for the treatment of migraine headaches, marketed to hospitals and healthcare providers in the United States.
• Phenylephrine Injection 10mg/mL Generic injectable vasopressor (phenylephrine 10mg/mL) used to treat hypotension during surgical procedures, available in 1mL, 5mL, and 10mL formulations and marketed to U.S. hospitals and surgical centers.
• Piperacillin and Tazobactam for Injection Generic broad-spectrum antibiotic combination injection available in multiple strengths (3g/0.375g, 4g/0.5g, 12g/1.5g, 36g/4.5g) for treating susceptible bacterial infections, marketed to U.S. hospitals.
• Sodium Acetate Injection Generic injectable sodium supplement used to supply sodium in large intravenous fluids for patients who cannot take fluids orally, available in 20mL, 50mL, and 100mL formulations and in 2mEq/mL and 4mEq/mL concentrations, marketed to U.S. healthcare providers.
• Tranexamic Acid Injection 100mg/mL Generic antifibrinolytic injection (100mg/mL) used to reduce or prevent excessive bleeding, available in standard and Novaplus-branded formulations and marketed to U.S. hospitals.
• Tromethamine Injection Generic version of THAM (Tromethamine Injection) indicated for the prevention and correction of metabolic acidosis, available as 30 mEq/100 mL in 500 mL single-dose glass vials, marketed to U.S. hospitals as Milla's first self-commercialized product.
• Acetaminophen IV (Paracetamol IV) Generic injectable acetaminophen (paracetamol IV) used for pain relief and fever reduction in adult and pediatric patients two years and older, commercialized in the U.S. through partner Sandoz.
• Dexmedetomidine Hydrochloride Injection Generic injectable sedative (dexmedetomidine hydrochloride) used in critical care and procedural sedation, marketed to U.S. hospitals following FDA ANDA approval.
• Magnesium Sulfate in Water for Injection Generic magnesium sulfate injection in non-PVC, single-patient use containers indicated for prevention and control of seizures in preeclampsia and eclampsia, marketed to U.S. hospitals and obstetric care providers.
• Pyridostigmine Bromide Syrup 60 mg/5mL Generic oral syrup version of Mestinon (pyridostigmine bromide 60 mg/5mL) indicated for symptomatic treatment of myasthenia gravis, marketed to U.S. healthcare providers and pharmacies.

Named customers6 records

Segments1 record

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Three partnerships are on record, tiered core.

• Woodward Pharma Services LLCcoreChannel Partner/ Reseller/ Distributor · 9 January 2024Woodward Pharma Services LLC commercialized the supplemental Abbreviated New Drug Application (sANDA) approval from FDA for a generic version of Sodium Acetate Injection 4 mEq/mL. This partnership expands access to sodium acetate products in the US market.
• SandozcoreChannel Partner/ Reseller/ Distributor · 8 December 2020Sandoz launched generic injectable acetaminophen (paracetamol IV) developed by Milla Pharmaceuticals. This was the first Alter Pharma Group product to enter the US market, demonstrating the partnership's importance in Milla's US expansion strategy.
• A.forallcoreStrategic or Co-development PartnerA.forall is the Belgian parent company of Milla Pharmaceuticals. The group has headquarters in Anderlecht (Belgium) with offices in Ireland and the United States. A.forall is a global player on the generics market with around 30 molecules on the European and US market and a fully stocked pipeline of niche, complex and added value products. Total group employs 144 employees.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Fresenius Kabi: Major hospital-channel supplier of sterile injectables and IV generics in the US; directly comparable commercially as a broad incumbent in the institutional injectable market Milla targets.
• Sandoz: Global generics leader and a current commercialization partner of Milla; competes broadly in US injectable generics while also distributing partner-developed products like Milla's acetaminophen IV.
• Eugia Pharma (Aurobindo): US sterile injectables subsidiary of Aurobindo, one of the largest global generic manufacturers; competes with Milla in the hospital injectable channel with materially larger scale.
• Dr. Reddy's Laboratories: Diversified global generics manufacturer with a substantial sterile injectables portfolio including shortage-listed molecules comparable to Milla's Sodium Acetate and Magnesium Sulfate.
• Apotex: Large Canadian-headquartered generics company with a meaningful sterile injectable footprint; serves US hospital channels on overlapping molecules to Milla's portfolio.

Direct peers

• Lannett: US-headquartered generic manufacturer with a hospital/injectables segment; comparable in scale and channel focus to Milla's US injectable generics commercialization platform.
• Amphastar Pharmaceuticals: US-based specialty pharmaceutical company focused on generic injectables, inhalation, and intranasal products — directly comparable to Milla's injectable generics focus on hospital and shortage-listed products.
• Hikma Pharmaceuticals: Global generic injectables manufacturer with strong US hospital channel presence; competes head-to-head with Milla in many of the same molecules and shortage-targeted injectable categories.
• Woodward Pharma Services: Smaller US specialty generic firm and Milla's commercialization partner on Sodium Acetate Injectables; directly comparable niche-commercialization model for shortage-targeted injectables.

Emerging players

• Civica Rx: Non-profit generic drug enterprise specifically formed to address US drug shortages; directly aligned with Milla's shortage-focused injectable thesis and likely to overlap on key molecules.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/milla-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Milla Pharmaceuticals Inc.